Granulomatous infectious diseases associated with tumor necrosis factor antagonists

The relationship between the use of tumor necrosis factor antagonists and onset of granulomatous infection was examined using data collected through the Adverse Event Reporting System of the US Food and Drug Administration for January 1998 - September 2002. Granulomatous infections were reported at rates of similar to 239 per 100,000 patients who received infliximab and similar to74 per 100,000 patients who received etanercept (P<.001). Tuberculosis was the most frequently reported disease, occurring in ∼ 144 and ∼ 35 per 100,000 infliximab-treated and etanercept-treated patients, respectively (P<.001). Candidiasis, coccidioidomycosis, histoplasmosis, listeriosis, nocardiosis, and infections due to nontuberculous mycobacteria were reported with significantly greater frequency among infliximab-treated patients. Seventy-two percent of these infection occurred less than or equal to 90 days after starting infliximab treatment, and 28% occurred after starting etanercept treatment (P < .001). These data indicate a risk of granulomatous infection that was 3.25-fold greater among patients who received infliximab than among those who received etanercept. The clustering of reports shortly after initiation of treatment with infliximab is consistent with reactivation of latent infection.